The five-year-old startup said it will use the funding to develop new products.
Bluepha received a cumulative B1 and B2 funding of nearly CNY 700 million in February and August 2021, respectively. The Series B financing funds will be used to advance construction and operation for the biodegradable material PHA, the development and deployment of SynBio_OS, an Industry 4.0 synthetic biology R&D platform, and the implementation of new product pipelines such as regenerative medicine materials and engineered probiotics.
The B3 round of financing was jointly led by Genesis Capital and Mixed Reform Fund. Zhongping Capital, Jiangsu Huanghai Financial Holding Group, and Zhongzhou Lanhai also participated in the investment, with existing shareholders Fengrui Capital, Country Garden Ventures, Hillhouse Ventures and Sanyi Innovation Investment continued to back the investments and Taihe Capital as the exclusive financial advisor.
Founded in 2016, Bluepha is dedicated to designing, developing, manufacturing and marketing novel bio-based molecules and materials.
It is expected that SynBio_OS will be able to shorten the complete development cycle of individual products of Bluepha by 70% from the existing model within the next 3 years.